RBC Capital lowered the firm’s price target on Viridian Therapeutics (VRDN) to $30 from $42 and keeps an Outperform rating on the shares. Amgen’s (AMGN) Tepezza-OBI showed better numerical results than Viridian’s ele’ on proptosis responder rate, though RBC still sees a meaningful $1B market opportunity for Viridian’s TED franchise by 2030 with conservative patient penetration, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics removed from Best Ideas List at Wedbush
- Viridian: Pullback Seen as Overdone as Veligrotug Convenience and TED Portfolio Underscore Buy Rating
- Leerink sees weakness in Viridian Therapeutics shares as ‘overdone’
- Buy Rating on Viridian: Elegrobart’s Convenience Edge and Overdone Share Price Pullback in Thyroid Eye Disease
- Midday Fly By: Neurocrine to acquire Soleno, Oracle hires new CFO